Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone + tobramycin is a fixed-dose combination ophthalmic medication consisting of the synthetic corticosteroid dexamethasone and the aminoglycoside antibiotic tobramycin. This combination is indicated for steroid-responsive inflammatory ocular conditions where a bacterial infection exists or there is a high risk of infection. Dexamethasone provides potent anti-inflammatory action by inhibiting the release of inflammatory mediators and suppressing the immune response, while tobramycin offers broad-spectrum bactericidal activity against common ocular pathogens by inhibiting bacterial protein synthesis. In the context of the REPEX clinical trial conducted by Azienda USL Reggio Emilia - IRCCS, this combination was utilized as the standard postoperative treatment to manage inflammation and prevent infection in patients with pseudoexfoliation syndrome (PEX) undergoing cataract surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + tobramycin.